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Abstract
The matrix/capsid processing site in the HIV-1 Gag precursor is likely the most sensitive target to
inhibit HIV-1 replication. We have previously shown that modest incomplete processing at the site
leads to a complete loss of virion infectivity. In the current study, a sensitive assay based on
fluorescence polarization is described that can monitor cleavage at the MA/CA site in the context
of the folded protein substrate. The substrate, an MA/CA fusion protein, was labeled with the
fluorescein-based FlAsH (Fluorescein Arsenical Hairpin) reagent which binds to a tetracysteine
motif (CCGPCC) that was introduced within the N-terminal domain of CA. By limiting the size of
CA and increasing the size of MA (with an N-terminal GST fusion), significant differences in
polarization values were measurable as a function of HIV-1 protease cleavage. The sensitivity of
the assay was tested in the presence of increasing amounts of an HIV-1 PR inhibitor, which
resulted in a gradual decrease in the FP values demonstrating that the assay is sensitive discerning
changes in protease processing. The high-throughput screening assay validation in 384-well plates
showed that the assay is reproducible and robust with an average Z'–value of 0.79 and average
coefficient of variation values less than 3%. The robustness and reproducibility of the assay was
further validated using the LOPAC1280 compound library, demonstrating that the assay provides a
sensitive high-throughput screening platform that can be used with large compound libraries for
identifying novel maturation inhibitors targeting the MA/CA site of the HIV-1 Gag polyprotein.
INTRODUCTION
The processing of the HIV-1 polyproteins Gag and Gag-Pro-Pol by the virally encoded
protease (PR) is an indispensable step in the formation of mature infectious virus particles.
The processing of Gag and Gag-Pro-Pol occurs either shortly after virus budding or
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concomitantly with virus budding, releasing the mature virion proteins [matrix (MA), capsid
(CA), spacer peptide 1 (SP1), nucleocapsid (NC), spacer peptide 2 (SP2) and p6] from Gag,
and the viral enzymes including the viral protease from Gag-Pro-Pol.1 Upon Gag
processing, there is a structural rearrangement that involves the released N-terminus of the
CA protein, which adopts a β-hairpin structure by forming a salt bridge between Pro1 and
Asp51 of CA,2–5 and this is a key element of the formation of the cone-shaped capsid shell
surrounding the NC/RNA nucleoprotein complex.6 Because proteolytic processing is
essential for generating infectious virus particles, PR has been the target of a very successful
group of transition state analog inhibitors currently in clinical use.7–14 Although a large
number of drugs have been developed for HIV-1 that collectively target entry, reverse
transcriptase, integrase, protease and maturation, and the use of these compounds in
multidrug regimens has dramatically reduced viral load as well as morbidity and mortality,
their long-term benefit in HIV-1-infected patients can be limited by the emergence of drug-
resistant viral strains. Moreover, resistance to one drug frequently confers some level of
cross-resistance to other drugs directed at the same target.15, 16 The use of frontline drugs in
intermittent prophylaxis17 provides another, large-scale setting where selection for
resistance after an undiagnosed transmission event may occur. Thus, there is a continuing
need to develop new drug targets for HIV-1.
HIV-1 particle assembly is a highly ordered process involving the association and
rearrangement of several thousand viral structural proteins,18 creating iterative targets in the
assembly of a single virion. The HIV-1 CA protein participates in crucial and repetitive
protein-protein interactions in forming both immature and mature virus particles either as a
part of the Gag polyprotein or as a processed protein, respectively.19–21 Due to the essential
role in the assembly of virus particles, the HIV-1 CA protein has been an attractive target for
the development of a new class of HIV-1 drugs. In recent years, inhibitors that bind to CA
and interfere with intermolecular CA-CA interactions have been developed, including
CAP-1, a small molecule inhibitor that binds to the N-terminal domain (NTD) of CA in a
hydrophobic pocket,22, 23 CAI, a 12-mer helical peptide, selected using phage display that
binds to a hydrophobic cleft within the C-terminal domain (CTD) of CA,24, 25 and
PF7426, 27 and two series of compounds based on benzodiazepines (BD) and benzimidazoles
(BM), new small molecule inhibitors of CA that also bind to the NTD of HIV-1 CA.28
Another new class of antiretrovirals targets the processing sites of the structural polyprotein
Gag. Inhibitors targeting the Gag processing sites are termed “maturation inhibitors”.
Bevirimat, which was identified in a screen for inhibition of viral replication, is the
prototype HIV-1 maturation inhibitor and represents a proof-of-concept for the inhibition of
the cleavage of a specific processing site, CA/SP1 of the HIV-1 Gag polyprotein29, 30,
although it was not successful as a therapeutic agent due to naturally occurring Gag
polymorphisms around the CA/SP1 processing site that confer resistance to the drug.31–33
Bevirimat is incorporated into immature particles near the CA-SP1 processing site and
stabilizes an immature form of the CA lattice, altering the ability of Gag to serve as a PR
substrate at the CA-SP1 site.34, 35 Recently, direct binding of bevirimat to the CA-SP1
processing site in immature Gag particles has been demonstrated.36
Previously, we have shown that a mutation (Y132I) that blocks cleavage at the HIV-1 MA/
CA processing site displays a strong transdominant effect when tested in a phenotypic
mixing strategy, inhibiting virion infectivity with an IC50 of only ≤4% of the mutant relative
to wild type.37 The viral infectivity was completely ablated with inclusion of 20% Y132I
mutant.37 This mutation is 10- to 20-fold more potent in transdominant activity than an
inactivating mutation in the viral protease, the target of many successful inhibitors, and more
potent than an inactivating mutation at any of the other Gag processing sites including the
bevirimat-targeted site CA/SP1, making the MA/CA processing site likely the most sensitive
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site to inhibition in the entire viral life cycle. Others have reported a similar result, although
a higher (15~20%) amount of the Y132I mutant was required to reach half-maximal
inhibition.38 Additionally, this transdominant effect has been seen with murine leukemia
virus when the cleavage of the N-terminus of the MLV CA is blocked.39 The ability of a
small amount of the MA/CA fusion protein to poison the oligomeric assembly of infectious
virus suggests that the MA/CA processing site is an attractive target for drug development to
inhibit HIV-1 infection. Although the mechanism of the transdominant effect by the
inclusion of small amount of MA/CA fusion proteins in a virion is not fully understood,
virus containing 20% of Y132I and 80% of wild type protein shows an eccentric and
aberrant virion core, and the replication is blocked either at or before the initiation of reverse
transcription.37 Thus, CA assembly steps requiring multimeric interactions may be more
potent targets to inhibit viral replication than the current HIV-1 drug targets.
High-throughput screening (HTS) efforts have made a significant contribution to HIV-1
drug discovery. Integrase inhibitors were identified in a random screen of compounds
targeted at the strand-transfer reaction.40 The fusion inhibitor T20/Fuzeon was identified in
a screen of peptides spanning the Env protein with no knowledge of mechanism.41, 42
Several NNRTIs43 and the HIV-1 maturation inhibitor bevirimat44, 45 have been identified
in screens for inhibition of viral replication. In this paper, using a derivative of the naturally
folded Gag protein as a substrate, we describe the development of a new high-throughput
protease assay based on fluorescence polarization (FP) for screening inhibitors that can
block the cleavage event at the MA/CA processing site. Although FP has been extensively
used in protease assays46 and adapted to viral protease assays,47, 48 substrates used in the
assays have been fairly small. To screen inhibitors binding to the substrate in the context of
the naturally folded Gag proteins, an MA/CA fusion protein was used as a substrate and also
modified to allow binding of a fluorescent reagent and to create greater size asymmetry
between the labeled substrate and cleavage product. Using this substrate, we were able to
measure specific proteolysis by FP as a function of HIV-1 protease cleavage. Assay
validation in 384-well plates and a test screen with LOPAC1280 compound library indicate




The primers to construct plasmids used in this study were designed so that a His6-tag was
introduced at the N-terminus of each protein except for p15-C2S, for which a His6-tag was
introduced at the C-terminus. Unless specified, site-directed mutagenesis was performed
using mutagenic primers to resynthesize the target plasmid by PCR. The plasmid
pARKz1k1-5LTRgag, containing a fragment of 5’ LTR and gag region of pNL-CH, an
infectious molecular clone derived from the pNL4-3 clone of HIV-1,49 was used as a
template to amplify the full-length MA/CA coding region by PCR. The PCR product was
digested with NdeI, which was introduced in the PCR primers, and cloned into the NdeI site
of pET30b (Novagen) to generate the parental plasmid pMA/CA. A tetracysteine motif
(CCGPCC) was introduced within the NTD of CA (His 87-Ala 92) using pMA/CA as a
template. For pMA/CAΔ, two overlapping PCR fragments, one containing the coding region
for a glutathione S-transferase (GST) tag amplified from pET41b (Novagen) and the other
containing the full-length MA/CA coding region amplified from pMA/CA, were used in an
overlapping extension PCR. The resulting PCR product was cloned into the NdeI site of
pET30b, and then the CTD of CA was truncated by substituting Ser 278 with a stop codon.
To generate pMA/CAΔ-Y132I, a Y132I mutation was introduced at the P1 position of the
MA/CA cleavage site by site-directed mutagenesis using the pMA/CAΔ as the template. The
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structure of each of the constructs was confirmed by DNA sequence analysis. The constructs
used for the infection assay, Y132I and D25A, were described previously.37 To clone a p15
region containing NC, SP2, and p6 domains into the pET30b vector, a DNA fragment
encoding the NC, SP2, and p6 domains derived from pNL-CH was synthesized and cloned
into a pMA-T vector by GeneArt (Invitrogen). This p15 DNA fragment contains several
modifications. All the cysteine residues in the zinc finger motifs were replaced with serine
and the C-terminal 6 amino acids (SDPSSQ) in the p6 domain were changed to CCPGCC to
introduce a tetracysteine motif. In addition, a Gly-Ser-Gly linker and a His6-tag were added
downstream of the tetracysteine motif. This modified p15 DNA fragment was subcloned
into the NdeI site of pET30b (Novagen) using NdeI sites introduced to flank the p15 DNA
fragment, generating pET-p15-C2S.
Cell Culture and DNA Transfection
293T cells and the TZM-BL cells (NIH AIDS Research and Reference Reagent Program)
were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf
serum in the presence of penicillin and streptomycin at 37°C with 5% CO2. 293T cells are
derived from human embryonic kidney cells50, and TZM-BL cells are HeLa cells that stably
express CXCR4, CCR5, and CD451. For cotransfection, 0.5 × 106 293T cells were seeded
onto a six-well plate 24 h before transfection. 293T cells were transfected with a total of 4
µg of wild-type and mutant plasmid constructs using FuGENE 6 transfection reagent
(Promega).
Infectivity Assay
The culture supernatant containing virus particles was harvested 48 h after transfection and
filtered through a 0.45-µm-pore-size membrane (Millipore) to remove cell debris. The
culture supernatant was diluted 1:50 or 1:100 and used to infect 2 × 104 TZM-BL cells in a
96-well plate. The TZM-BL indicator cells express the luciferase gene and the lacZ gene
under the control of the HIV-1 LTR. For the luciferase assay, infected TZM-BL cells were
lysed 48 h postinfection. Briefly, the culture medium was removed from each well, and the
cells were washed with phosphate-buffered saline. A 50 µL aliquot of 1× reporter lysis
buffer (Promega) was added to the cells, and the cells were kept at −80°C. After one freeze-
thaw cycle, 25 µL of cell lysate was transferred into a 96-well assay plate (Costar), and
luciferase activity was measured using a luminometer (Promega).
Expression and Purification of HIV-1 PR Substrates
Expression of recombinant proteins in E. coli BL21 (DE3) was carried out by a modification
of the established protocols. 52, 53, Briefly, recombinant proteins were expressed in E. coli
BL21 (DE3) grown in MagicMedia (Invitrogen) for 7 h and the cells were collected by
centrifugation. The cell pellet was lysed in Tris-buffered saline (25 mM Tris base, 3 mM
KCl, and 140 mM NaCl) at pH 7.5 with 1 mM dithiothreitol (DTT) and 1% Triton X-100
then sonicated. Following clarification by centrifugation, the recombinant proteins
containing a His6-tag at the N-terminus were purified from the soluble fraction by affinity
chromatography using a nickel-chelating column (Novagen). The purified recombinant
proteins were dialyzed against 20 mM sodium acetate (pH 7.0), 1 mM EDTA, 2 mM DTT,
and 10% glycerol.54 The p15-C2S protein was purified under denaturing conditions during
the nickel-chelating column chromatography (Invitrogen) and refolded by a step-wise
dialysis. The dialysis buffers used for refolding contained 5 M urea, 400 mM NaCl, 12.5%
glycerol, and 2.5 mM DTT at pH 5.5 for the initial dialysis, 2 M urea, 400 mM NaCl, 12.5%
glycerol, and 2.5 mM DTT at pH 6.0 for the second dialysis, and 400 mM NaCl, 12.5%
glycerol, and 2.5 mM DTT at pH 6.5 for the last dialysis. Protein concentrations were
determined by using the Bradford assay, and the purity of the preparations was analyzed by
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protein staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE).55
Protease Expression and Purification
The HIV-1 protease was expressed in E. coli TAP 106 cells and purified from inclusion
bodies as previously described.56 Briefly, the inclusion body centrifugation pellet was
dissolved in 50% acetic acid followed by another round of centrifugation to remove
impurities. Size exclusion chromatography was used to separate high molecular weight
proteins from the protease. The protein was refolded in 50 mM sodium acetate at pH 5.5, 5%
ethylene glycol, 10% glycerol, and 5 mM DTT.
Gel-based HIV-1 Protease Assay using FlAsH-labeled Protein Substrates
The gel-based HIV-1 protease assay was carried out following the protocol described
previously.57 Briefly, 3 µM of each of two substrates, MA/CA and MA/CAΔ, were labeled
with 6 µM FlAsH reagent in a tube with a total volume of 228 µL overnight at room
temperature. Proteolysis of the substrates was performed in the proteolysis buffer (50 mM
sodium acetate, pH 7.0, 150 mM NaCl, 1 mM EDTA, 2 mM 2-mercaptoethanol, and 10%
glycerol) at 30°C by addition of 0.1 µM HIV-1 PR (50 nM dimeric HIV-1 PR based on
protein concentration). Aliquots of 24 µL were taken at various time points and the reaction
was stopped by adding 4× SDS-PAGE loading buffer for further analysis by SDS-PAGE.
An aliquot of 24 µL was taken for the 0 min time point prior to the addition of 50 nM HIV-1
PR. After SDS-PAGE, the gels were briefly rinsed with water and the fluorescently labeled
protein bands were visualized by fluorescence imaging using a Typhoon 9400 (GE
healthcare) with excitation at 488 nm and emission at 526 nm.
FP Assay in a 96-well Plate
For end-point analysis, the substrate MA/CAΔ was serially diluted 2-fold from 4 µM to 0.25
µM in a 96-well half-area plate (Costar) and 200 nM FlAsH reagent was added to each well
for the overnight labeling reaction in a volume of 40 µL. The labeling reaction was
performed at room temperature in proteolysis buffer. The well designated as 0 µM substrate
contained only 200 nM FlAsH reagent. After the labeling reaction, proteolysis was
performed in the absence or presence of 1 µM PR at 30°C for 3 h in a final volume of 50 µL,
and then FP values were measured with excitation at 480 nm (30 nm bandpass) and emission
at 535 nm (40 nm bandpass) using a PerkinElmer En Vision 2103 Multilabel Reader. For the
time course analysis, 200 nM FlAsH reagent was incubated overnight (~15 h) with 2 µM
substrate at room temperature in the same proteolysis buffer described above. An aliquot of
HIV-1 PR was added to make the PR 50 nM in the reaction volume containing the substrate
MA/CAΔ labeled with a FlAsH reagent. The final volume in each well was 50 µL.
Immediately after the addition, the reactions were mixed briefly by pipetting and the FP
value was recorded every 5 min for 3 h using the same conditions as described for the end-
point analysis. For the FP assay in the presence of saquinavir (SQV), 1 nM, 10 nM, 15 nM,
20 nM, or 25 nM SQV was added in DMSO (4% final concentration) to the reaction prior to
the addition of the PR. FP values are presented as millipolarization units (mP) in which P
can be calculated by a standard equation.58
HTS Assay Validation in 384-well Plates
The FP assay was validated in 384-well plates following the procedure described for 96-well
plate with modifications. An aliquot of 22 µM MA/CAΔ substrate was labeled with 2 µM
FlAsH reagent in 50 mM HEPES buffer at pH 6.8 containing 1 mM DTT at room
temperature for 1 h. Proteolysis in a 384-well plate was performed by the addition of 50 nM
HIV-1 PR in the presence of 50 mM HEPES at pH 6.8, 150 mM NaCl, 2 mM DTT, 0.01%
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BSA, and 1% DMSO at 37°C for 2 h. The final concentration of the substrate MA/CAΔ in
the proteolysis reaction was 1 µM and the final volume in each well was 30 µL. FP values
were measured with excitation at 485 nm and emission at 530 nm using an Aquest GT
Multimode Microplate Reader (Molecular Devices). All liquid handling was operated by
NanoScreen Robot NS-1536 (NanoScreen). The validation process was carried out on three
consecutive days and two plates were assayed on each day. Each assay plate contained two
columns of positive and negative control wells containing wild-type HIV-1 PR and heat-
inactivated HIV-1 PR, respectively. All raw data were analyzed using ScreenAble
(ScreenAble Solution) to determine Z′-value and coefficient of variation (CV) for each
plate.
Test Screening with LOPAC1280 Compound Library
The Library of Pharmacologically Active Compounds (LOPAC) was purchased from
Sigma-Aldrich, dissolved in DMSO by the manufacturer. Each compound was stored in
DMSO to a concentration of 10 mM in 384-well plates. For the screening, each compound
was further diluted to a concentration of 100 µM in the HEPES-based proteolysis buffer.
The LOPAC collection was screened in duplicate in 384-well plates. Briefly, 13.5 µL of 2.2
µM MA/CAΔ labeled with FlAsH tag, 13.5 µL of 110 nM HIV-1 PR, and 3 µL of the diluted
compound were transferred into the assay plate, and the plate was incubated at 37°C for 3 h
before measuring FP values using an Aquest GT Multimode Microplate Reader (Molecular
Devices). The final volume in each well was 30 µL and the final concentration for each
compound, the HIV-1 PR, and the substrate in each assay reaction was approximately 10
µM, 50 nM, and 1 µM, respectively. All liquid handling was operated by a NanoScreen
Robot NS-1536 (NanoScreen). Each assay plate contained two columns of positive and
negative control wells, which were run with DMSO alone without a compound. The positive
control wells contained wild-type HIV-1 PR and the negative control wells contained heat-
inactivated HIV-1 PR. Raw data were analyzed using ScreenAble (ScreenAble Solution) to
determine Z′–value, CV, and percent inhibition of each assayed compounds. To calculate
the percent inhibition of cleavage, the mean value from the positive control wells was
considered as 0% and the mean value from the negative control wells was considered as
100%. The degree of agreement between the two measurements was determined by Bland-
Altman analysis.59
Gel-based Secondary Assay
Secondary assays to confirm specificity of possible hits from the primary screening were
performed using two substrates, MA/CA and p15-C2S, in a gel-based proteolysis assay. For
labeling reactions, 1.5 µM of each of two substrates, MA/CA and p15-C2S, was incubated
with 4 µM FlAsH reagent in a tube overnight at room temperature in a volume of 200 µL,
and proteolysis of the substrates was performed in the proteolysis buffer at 30°C by addition
of 0.34 µM HIV-1 PR. Aliquots of 24 µL were taken at various time points (2.5 min, 5 min,
7.5 min, 10 min, 15 min, 20 min, and 60 min) and the reaction was stopped by adding 4×
SDS-PAGE loading buffer for further analysis by SDS-PAGE. An aliquot of 24 µL was
taken for 0 min time point prior to the addition of the HIV-1 PR. After SDS-PAGE, the gels
were briefly rinsed with water and the fluorescently labeled protein bands were visualized
by fluorescence imaging using a Typhoon 9400 (GE healthcare) with excitation at 488 nm
and emission at 526 nm. The relative quantitation of the visualized protein bands was
performed by using the image analysis software ImageQuant TL (GE healthcare).
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HIV-1 MA/CA Cleavage Site, a Sensitive Target to Inhibit Virus Replication
Recently, we have demonstrated that a modest lack of cleavage at the MA/CA processing
site of the HIV-1 Gag polyprotein has profound effects on viral infectivity,37 making this
processing site an attractive target to inhibit the viral life cycle. When viruses were
generated to contain different ratios of wild-type and Y132I mutant (which blocks cleavage
at the MA/CA site) Gag polyproteins by a phenotypic mixing strategy, a strong
transdominant effect of the Y132I mutation on the viral infectivity was observed. The IC50
of the Y132I mutant Gag protein was only ≤4%. To confirm our previous finding,
phenotypic mixing experiments were performed by cotransfecting two DNAs, wild type and
a mutant (either the Y132I Gag mutant or a D25A PR active site mutant), varying the ratios
of the wild-type and mutant genomes, and the infectivity of the virus produced was
measured. A similar result of a strong transdominant effect was observed from the virus
containing Y132I mutant Gag protein, with the IC50 of less than 4% (Figure 1A). Consistent
with the previous finding, the Y132I mutant displays approximately 20-fold more potency in
transdominance than the D25A PR mutant when the IC50 values of both mutants from the
cotransfecton assay were compared (Figure 1A). Western analysis of virus lysates
containing increasing amount of Y132I mutant Gag polyproteins shows inhibition of the
cleavage event at the MA/CA site giving a distinctive band pattern with increasing amount
of the MA/CA fusion protein in the virions (Figure 1B). However, the virus lysates
containing increasing amount of D25A mutant Gag polyproteins display a range of
processing intermediates including Gag precursors, a distinctive western-analysis phenotype
due to the reduction/inhibition of protease activity with the D25A mutation (Figure 1B).
Design and Expression of MA/CA Substrates
As a first step in searching for novel maturation inhibitors that would selectively block
proteolytic processing at the highly sensitive MA/CA site, we have developed a proteolytic
cleavage assay based on fluorescence polarization (FP) (Figure 2A) in both 96- and 384-well
plates using a series of naturally folded MA/CA protein substrates containing an intact MA/
CA cleavage site (Figure 2B). To monitor the cleavage at this site by the HIV-1 PR in either
an FP assay or a gel-based assay, a tetracysteine motif (CCGPCC) was introduced into a
surface loop region within the NTD of CA (amino acids 87 to 92) near the position
previously used to label intact virus60 to allow for FlAsH reagent binding. In Figure 2B, the
position of a tetracysteine motif is indicated with the symbol for the FlAsH tag. The
substrate containing MA and full-length CA domains with the tetracysteine motif in the
NTD of the CA is termed MA/CA. The FlAsH reagent is a nonfluorescent biarsenical
derivative of fluorescein that becomes fluorescent upon binding to its target,61 as illustrated
in Figure 2A. In a protease assay employing FP, the enzyme activity is measured by a
decrease in polarization values (mP) as the result of the change in size of the high-molecular
weight fluorescent substrate to the low-molecular weight cleavage product (Figure 2A).
Therefore, to increase differences in size before and after cleavage by the HIV-1 PR, the
original MA/CA substrate was altered to include a fusion of a GST tag to the N terminus of
MA and a truncation of the CTD of CA resulting in a protein substrate of 56 kDa (Figure 2A
and B). This prototype substrate is designated as MA/CAΔ. In our FP assay, the size
difference before and after proteolysis is approximately 41 kDa (56 kDa to 15 kDa; Figure
2A). The MA/CAΔ-Y132I substrate contains an additional Ile substitution at the P1 position
of the MA/CA cleavage site to block cleavage at the MA/CA site by the HIV-1 PR.37 These
substrates include a His6-tag at the N terminus of the protein to aid purification. When
expressed in E. coli, the soluble form of the proteins were made in large quantity and the
modifications and mutations made to the original MA/CA protein did not significantly affect
the solubility of the proteins. We also created p15-C2S substrate to examine cleavage at an
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alternative Gag cleavage site, SP2/p6, in a gel-based secondary assay. This protein substrate
contains the NC, SP2, and p6 domains with Cys to Ser substitutions in the zinc-finger motifs
within the NC domain and a tetracysteine motif introduced within the C-terminal region of
the p6 domain.
FP-based HIV-1 Protease Assay Development in 96-well Plates
We have demonstrated previously that the efficiency of cleavage of the substrate MA/CAΔ
(≅ 56 kDa) was not affected by the alterations made to the MA/CA protein (≅ 40 kDa) in a
gel-based assay. As shown previously57 and in Figure 3A, the two substrates, MA/CA and
MA/CAΔ, are versatile tools that can be used to study HIV-1 proteolysis in a gel-based
assay since the two full-length substrates and their cleavage products differ in size enabling
the use of both substrates in the same proteolysis reaction. The full length CA, shown in
open arrowhead in Figure 3A, is the cleavage product of the MA/CA substrate, and the
truncated CA, CAΔ, shown in closed arrowhead in Figure 3A, is the cleavage product of the
MA/CAΔ substrate. Given the equivalent cleavage rates of the modified and unmodified
substrates, the more asymmetric substrate, MA/CAΔ, was used in a fluorescence
polarization readout.
Fluorescence polarization is a convenient approach to measure the activity of a protease and
is amenable to high-throughput screening in a plate format. To develop an assay to screen
for small molecules that specifically block the MA/CA processing site, protease cleavage of
the substrate MA/CAΔ was measured by changes in FP values in a 96-well plate. The
optimum concentrations of FlAsH reagent and substrate for the FP assay were determined
by titrating the FlAsH reagent with the substrate MA/CAΔ. The largest differences in FP
values as a function of protease cleavage were observed with 200 nM FlAsH reagent (data
not shown). The formation of a high-molecular-weight fluorescent complex of the FlAsH
reagent bound to MA/CAΔ led to an increase in FP value until the FlAsH reagent was
saturated with the substrate (Figure 3B). The FP value approached a plateau when substrate
concentration was increased to 1 µM. Therefore, based on the titration data shown in Figure
3B, 2 µM substrate and 200 nM FlAsH were chosen as optimum concentrations for labeling
the substrate for the FP assay. In the presence of 1 µM HIV-1 PR, the FP value was
significantly reduced due to cleavage at the MA/CA site (Figure 3B). To define a protease
concentration for time-point FP analyses, 2 µM substrate was incubated with different
amounts of protease, and the result showed a useful concentration of protease to be 50 nM,
allowing cleavage of the substrate over a convenient period of time, 3 h (data not shown).
Under these conditions (substrate: 2 µM; FlAsH: 200 nM; HIV-1 PR: 50 nM), the time-point
FP values of MA/CAΔ gradually decreased over time due to cleavage at the MA/CA site
while the FP values in the absence of HIV-1 PR stayed high over a 3 h-time period, showing
no changes compared to the initial value (Figure 3C).
Highly Sensitive FP-based HIV-1 Protease Assay
When a substrate containing the Y132I mutation to block MA/CA cleavage was used in a
time-point FP assay, the FP values did not change over time (Figure 4A). After measuring
the FP values, a portion of the FP assay reaction was analyzed by SDS-PAGE to confirm the
state of the final cleavage products. The SDS-PAGE result shown by Coomassie staining
revealed that the extent of cleavage of the substrates was consistent with the extent of
proteolysis inferred from FP assay, and that the substrate and products were stable without
displaying any detectable degradation (data not shown). The sensitivity of the assay was also
tested in the presence of the HIV-1 PR inhibitor saquinavir (SQV). In the presence of
increasing amounts of SQV from 1 nM to 25 nM, the changes in FP values decreased due to
inhibition of PR activity by SQV (Figure 4B), although the 1 nM reaction includes a small
mP effect caused by the presence of 4% DMSO (from the addition of SQV). In the presence
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of 25 nM SQV, the FP values stayed as high as those in the absence of HIV-1 PR suggesting
that enzyme activity was essentially completely inhibited. Again, these FP data were
confirmed by the SDS-PAGE analysis with Coomassie staining showing a gradual decrease
in cleavage products, GST-MA and CAΔ, with increasing amounts of SQV (Figure 4C).
Thus, these results demonstrate that the FP assay is sensitive for discerning changes in
proteolytic processing as shown by the detectable change in FP in the presence of increasing
amounts of a protease inhibitors.
HTS Assay Validation in 384-well Plates
To screen a large number of compounds using an automated system in 384-well plates, we
first optimized the FP assay for this format. HTS assay validation was then performed on the
automated platform to determine the robustness and reproducibility of the assay by
calculation of the Z'–values and CV. HTS assay validation included three independent runs
on different days in which each run consisted of two 384-well plates, comprising a total of
six plates. Each plate contained two columns of positive controls (red wells) and two
columns of negative controls (green wells) having substrate plus wild-type PR and substrate
plus heat-inactivated PR, respectively (Figure 5A). The wells shown in yellow contained the
same reaction as in the positive control wells since no compound was tested in the HTS
validation assay. The results of these validation experiments are summarized in the Table 1
showing an average CV less than 3% and 2 % for the positive controls and the negative
controls, respectively, and an average Z'–value of 0.79. The data from the plate 1 is shown
in Figure 5B, showing that FP values for the positive and the negative controls stayed
constant across the plate with the average difference of approximately 140 mP between the
two controls. For this particular plate, the CV was 2.29% for the positive controls and 1.25%
for the negative controls, and the Z'–value was 0.83. These validation parameters indicate
that the assay presented in this study is robust, reliable, and suitable for HTS to identify
HIV-1 maturation inhibitors targeting the MA/CA cleavage site.
Assay Validation With the LOPAC1280 Compound Library
To validate further the utility and reproducibility of the assay, we conducted a pilot screen
using the LOPAC1280 compound library (Sigma-Aldrich) comprising 1,280 small-molecule
compounds with well-characterized pharmacological activities. Each compound was
screened in duplicate at a final concentration of 10 µM. Each plate also contained two
columns of positive controls (red wells) and two columns of negative controls (green wells)
as shown in Figure 5A. No compound was added to the control wells, and heat-inactivated
PR was used in the negative control wells. The values from these control wells were used to
determine the percentage of inhibition for each compound tested, setting the mean values
from the positive control wells as 0% inhibition and the mean values from the negative
control wells as 100% inhibition. When the percentage of inhibition of all compounds tested
in duplicate was plotted in Figure 6A, most of the compounds had no effect on cleavage of
the substrate by HIV-1 PR with % inhibition values less than 20% of the mean value of the
negative controls. In this screen, the two compounds, AC-93253 iodide and I-OMe
tyrphostin AG538 (shown in circles; Figure 6A), had a readout of approximately 50%
inhibition. However, results from the gel-based assay demonstrated that these two
compounds had no inhibitory activity (data not shown). It is possible that these compounds
caused protein aggregation resulting in relatively high FP values. Conversely, some
compounds generated FP values lower than the mean value of the positive controls. We
speculate that these small compounds are fluorescent themselves, contributing to the lower
FP values of the reaction.
To compare the two measurements from the LOPAC validation assay, the degree of
agreement between the two measurements of the percent inhibition was assessed by using
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Bland-Altman analysis by plotting the differences between the two measurements against
the averages of the two measurements (Figure 6B). The mean difference between two
measurements was −0.36 and the 95% limits of agreement, defined as the mean difference ±
2 standard deviations, ranged from −11 to 12. This small range of limits suggests good
agreement between two measurements. In addition, the plot shows no trend of systematic
bias. Overall, this pilot screen using the LOPAC1280 compound library confirmed the
reproducibility, robustness, and suitability of this assay for HTS with an average Z'-value of
0.81 and average CV values of 0.02 and 0.01 for positive controls and negative controls,
respectively.
We also tested the maturation inhibitor, bevirimat, in a 96-well plate for time-point analysis.
The compound was tested at a final concentration of 10 µM, a concentration 1000-fold
higher relative to the EC50 measured in cell culture. As expected given its specificity for
inhibition of the CA/SP1 cleavage site, bevirimat did not show any significant inhibitory
activity on cleavage at the MA/CA site in a gel-based assay (data not shown). In a FP assay,
bevirimat had no inhibitory activity on cleavage at the MA/CA site beyond the small effect
caused by the presence of 5% DMSO included in the reaction (data not shown).
Gel-based Secondary Assay Using an Alternative Gag Cleavage Site
It is possible that the hits from the large-scale primary screening may target the protease
instead of the MA/CAΔ substrate as the mechanism of blocking the proteolysis reaction.
Since the goal of this HTS assay is to discover compounds that target the substrate in a
specific manner, we developed a secondary assay to examine the specificity of compounds
for the MA/CAΔ substrate and not for the protease using a protein substrate containing an
alternative Gag cleavage site. A substrate (p15-C2S) containing the continuous NC, SP2,
and p6 domains of Gag includes the relatively efficiently cleaved processing site between
SP2 and p6, as shown in Figure 7A. Since the FlAsH reagent appears to bind the NC domain
through the zinc finger motifs (unpublished data), all the cysteines in the zinc finger motifs
in the p15-C2S were replaced with serines, and a tetracysteine motif was introduced at the
C-terminus of the p6 domain to bind the FlAsH reagent. Using this gel-based secondary
assay, the level of specific inhibition for MA/CA can be determined by comparing the
relative cleavage rate of this substrate versus the p15-C2S substrate (mixed in the same
reaction) in the absence or presence of hit compounds. Compounds that inhibit only the MA/
CA substrate would be considered as maturation inhibitors specific for the MA/CA cleavage
site. In this secondary assay format, instead of using the MA/CAΔ substrate, the MA/CA
substrate was used for better separation of the uncleaved and cleaved protein bands of the
p15-C2S substrate. Figure 7B shows the relative cleavage rates of the MA/CA and p15-C2S
substrates. Cleavage at the SP2/p6 site was approximately 3.7-fold slower than cleavage at
the MA/CA site. Since cleavage at the NC/SP2 site is much slower than at the SP2/p6 site
(Figure 2B),62 proteolysis at the NC/SP2 site is not detected in this assay. Although cleavage
of the p15-C2S substrate is slower than the MA/CA substrate, the ability to include these
two substrates in a single reaction will provide strong evidence for the specificity of any
compounds identified by HTS.
DISCUSSION
There are 24 drugs approved for the treatment of HIV-1 infection, which target only four
viral proteins [reverse transcriptase (RT), protease (PR), integrase (IN), the viral
transmembrane envelope (Env) glycoprotein gp41] and one cellular protein [cellular co-
receptor (CCR5)]. Current HIV-1 therapy can require a change in drug regimen due to the
rise of drug resistance mutations or the adverse effect of toxicity of the drugs. However, the
outcome of a change in drug regimen can be suboptimal since resistance can confer cross-
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resistance to some of the drugs within the same class. Thus, there is an ongoing effort to
develop new classes of HIV-1 inhibitors.
The HIV-1 processing/capsid assembly pathway is an attractive but under-utilized target for
the development of HIV-1 inhibitors. This step of the virus life cycle could be the most
effective drug target since only a single structural protein, CA, released from the Gag and
Gag-Pro-Pol proteins drives the capsid assembly by the formation of repetitive interactions
to build a cone-shaped capsid structure, and the formation of the proper capsid structure is
essential for the production of infectious virus particles.1 The repetitive nature of these
interactions may provide an opportunity to disrupt many interactions with a single agent.
Furthermore, disrupting even a fraction of these interactions has the potential to ablate the
infectivity of the entire particle. We have demonstrated the vulnerability of the HIV-1 capsid
structure to inhibition by blocking the cleavage event at the N-terminus of the CA protein
creating MA/CA fusion protein in a virion.37 Only small amounts of unprocessed MA/CA
fusion protein, as little as 10% of the processed wild-type CA protein, in a virion were
sufficient to render the virion noninfectious (Figure 1). The most plausible explanation is
that the unprocessed MA/CA fusion protein is able to participate in the formation of the
cone-shaped capsid structure but in so doing aberrantly anchors parts of this structure to the
membrane via the membrane-linked MA domain, which is consistent with the acentric,
membrane-proximal cores that are seen in these virions. Due to the multiplicative effect on
the assembly process, we believe that the MA/CA processing site may be the most sensitive
target in the entire HIV-1 replication machinery.
Given the extreme vulnerability of the cleavage event at the N-terminus of the CA protein,
we have developed a sensitive HIV-1 protease assay based on fluorescence polarization
technology that is suitable for a large-scale screening for inhibitors that can block this
processing event. In this assay, a large native protein rather than a peptide was used as a
substrate. Proteolysis of the Gag and Gag-Pro-Pol polyproteins by the HIV-1 PR can be
influenced by the environment surrounding the cleavage site57 and mutations in the Gag
domain distal from the cleavage site can contribute to PI resistance.63, 64 Thus, using a
normal protein substrate containing the Gag cleavage site is crucial to finding inhibitors that
function in the context of the folded Gag protein. It is noteworthy that our assay would not
identify compounds such as bevirimat whose inhibition is specific to Gag proteins
assembled into an immature capsid-like structure.65 However, using a native soluble protein
substrate offers the potential advantage of screening drugs that can function in the context of
both the unassembled Gag protein and Gag proteins assembled into an immature capsid-like
structure. The protein substrate used in this study can be expressed in large quantities in E.
coli, and the purified protein is stable and easily purified. The assay was sensitive to
detecting inhibition, and the assay was easily optimized into 384-well plates. The HTS
validation of the assay generated an average Z'–value of 0.79, and CV of < 3% for the
positive controls and < 2% for the negative controls. Further assay validation with
LOPAC1280 compound library showed an average Z'–value of 0.81, and CV of 0.02% for
the positive controls and 0.01% for the negative controls, indicating that this assay is robust,
reliable, and highly suitable for screening a larger compound libraries to identify novel
HIV-1 maturation inhibitors specifically targeting the MA/CA cleavage site. This assay will
reveal both inhibitors of the substrate and the protease. However, an alternative substrate,
p15-C2S containing the SP2/p6 cleavage site, in the secondary assay will allow us to
identify inhibitors that are specific to the MA/CA cleavage site. Similarly, the distinctive
phenotype of inhibition of cleavage at this site is easily seen in virus particles produced in a
cell culture system (Figure 1B). It is also possible to develop another FP-based high-
throughput secondary assay using heterologous MA/CA proteins containing an HIV-1 Gag
cleavage site other than the MA/CA site to assess specificity.
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Recently, Breuer et al. reported a HIV-1 protease-substrate cleavage assay using native
domains of Gag substrate containing embedded processing sites.66 In this assay, substrates
are expressed as a GST and fluorescent reporter fusion protein. The substrates are coupled to
a bead through GST/anti-GST antibody interactions, and the cleavage reaction is detected by
the loss of fluorescence by flow cytometry. This assay uses native-folded substrates and is
sensitive to detecting cleavage reactions, however, the assay requires a washing step to
remove the released cleavage products from the beads. In contrast, our assay, based on
fluorescence polarization technology, offers several key advantages in an HTS platform.
First, the assay detects only the labeled molecules and distinguishes the cleaved substrates
from the uncleaved substrates enabling the assay to be done without the need of a washing
step. Second, FP reactions are performed in solution without solid supports allowing the
analysis to be more similar to physiological conditions. Finally, FP measures data from
kinetic and endpoint analysis in realtime. An FP-format assay can be used for other cleavage
sites in Gag although some of the constructs are limited by the fact that the NC protein with
its zinc fingers binds the FlAsH tag in the absence or presence of a tetracysteine motif (data
not shown).
The search for inhibitors of HIV-1 has demonstrated the utility of large-scale screens to
identify inhibitors with novel mechanisms of action, such as non-nucleoside reverse
transcriptase inhibitors (NNRTI)43 and the maturation inhibitor bevirimat.44, 45 Similarly,
inhibitors with novel mechanisms of action have been discovered using more targeted
screens, such as for inhibitors of the strand-transfer reaction of integrase40 or inhibitors of
viral entry by peptides derived from the Env protein.41, 42 What is common in all of these
efforts is that there was no a priori conceptualization of what the nature of the inhibitor
would be or the mechanism by which it would work in interacting with the target viral
protein. These efforts all resulted in new inhibitors of HIV-1 but also created a conceptual
framework for types of inhibitors that could be pursued in a more targeted way for other
agents. Thus, our deep understanding of the details of HIV-1 replication can provide new
opportunities to develop inhibitors of HIV-1 and also reveal new generalizable strategies for
potential targets of other agents. With both of these ideas in mind we are pursuing the
discovery of inhibitors with a novel mechanism of action against HIV-1. In summary, we
demonstrated an FP-based HIV-1 protease assay targeting the MA/CA cleavage site, an
extremely sensitive target to inhibit viral replication, using a folded globular substrate. We
have shown that this assay is robust and highly amenable to a HTS platform. We have also
shown that secondary assays are readily available to confirm the mechanism of action of
novel inhibitors of the MA/CA cleavage site. Collectively, these tools will permit large-scale
screening to search for new inhibitors with novel mechanisms targeted to this exquisitely
sensitive step in the virus life cycle.
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A strong transdominant mutation, Y132I, blocking cleavage at the MA/CA site of HIV-1
Gag polyprotein. (A) A transdominant effect of Y132I on wild-type viral infectivity in a
phenotypic mixing experiment. 293T cells were co-transfected with Y132I mutant and wild-
type plasmid DNAs with varying the ratio of the mutant from 0% to 100%. The culture
supernatant was harvested 48 h after transfection and used to infect TZM-BL cells. Infected
TZM-BL cells were lysed 48 h postinfection and infectivity was measured by the level of
luciferase activity. The transdominant effect of D25A, protease active site mutation, on
wild-type viral infectivity is shown for direct comparison. The inset graph represents relative
viral infectivity of Y132I mutant at a low range of mutant ratio from 0% to 20%. (B)
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Western analysis of virion particles produced from 293T cells co-transfected with wild type
and Y132I or D25A mutant DNAs. Mock represents a transfection where no DNA was used.
The mutant ratio (%) used for co-transfection is shown above the western blotting image.
MA/CA fusion proteins are shown from the virions containing Y132I mutant Gag/Gag-Pro-
Pol polyproteins and unprocessed Gag polyproteins and processing intermediate products
are shown from the virions containing D25A mutant Gag-Pro-Pol polyproteins.
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Overview of the FP-based HIV-1 protease assay and schematic diagram of the MA/CA
constructs used in the assay. (A) The FP assay detecting the changes in size of the
fluorescently labeled protein upon proteolysis. The free FlAsH tag animated in gray
increases in fluorescence after binding to a tetracysteine motif in the NTD of CA (CAN),
which is animated in black. The CAN labeled with a FlAsH reagent is also shown in black.
In the presence of the HIV-1 PR, the slowly rotating 56 kDa substrate releases the fast
rotating 15 kDa CAN resulting in a reduced FP value. (B) MA/CA-derived constructs in the
E. coli expression vector pET30b. All of the constructs contain an intact MA domain and the
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CAN. The MA/CA construct contains an intact MA domain and a full-length CA domain. A
tetracysteine motif (CCGPCC) is inserted within the CAN and the position of the
tetracysteine motif is indicated with a FlAsH tag symbol. The gray boxes located either at
the N-terminus or at the C-terminus of each construct represent a His6-tag. For MA/CAΔ
constructs, a GST tag is fused to the N-terminus of the MA domain to increase the size of
the protein. The p15 derived p15-C2S protein construct shows Cys→Ser mutations within
the zinc-finger motifs in the NC domain and amino acid substitutions within p6 to create a
tetracysteine motif. The cleavage sites between MA and CA, and between SP2 and p6 are
indicated with a scissor graphic. The slow cleavage event at the NC/SP2 site is depicted with
a small scissor.
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Detection of the cleavage of the MA/CAΔ substrate labeled with a FlAsH tag by gel-based
assay and FP assay in a 96-well plate. (A) Fluorescence image of the gel-based assay
employing two substrates. MA/CA and MA/CAΔ were labeled with the FlAsH reagent in
the same reaction, and proteolysis was performed by the addition of 50 nM HIV-1 PR at
30°C. Proteolysis was stopped at the various time points shown above the gel image for
further SDS-PAGE analysis. The aliquot for 0 min time point was taken before the enzyme
was added. Fluorescently labeled proteins were visualized by fluorescence imaging. Filled
arrowheads indicate MA/CAΔ substrate and its cleavage product (CAΔ) and open
arrowheads indicate MA/CA substrate and its cleavage product (CA). The domain shown in
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black (CAN) indicates the location where the FlAsH reagent binding occurred. (B) Cleavage
of the MA/CA site of the MA/CAΔ substrate measured by fluorescence polarization. End-
point analysis shows reduced FP values in the presence of HIV-1 PR as a function of
substrate concentration. Increasing amounts of MA/CAΔ (0 µM, 0.25 µM, 0.5 µM, 1 µM, 2
µM, and 4 µM) were incubated with 200 nM FlAsH reagent overnight, proteolysis was
performed at 30°C for 3 h in the absence (open circle) or presence (closed circle) of 1 µM
HIV-1 PR, and FP values were measured. (C) Time-point analysis of FP assay. The assay
was performed in the presence of 2 µM substrate and 200 nM FlAsH reagent. Immediately
after adding 50 nM PR, FP values were measured over 3 h-time period with 5-min intervals.
The reading collected from the well in which protease was not added was considered as 0
min time point.
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Highly sensitive FP-based HIV-1 protease assay. (A) FP values of the Y132I mutant
substrate, MA/CAΔ-Y132I, in the presence of PR (Δ) and the MA/CAΔ substrate in the
absence of PR (×) measured at 30°C for 3 h. (B) FP values of the MA/CAΔ in the presence
of increasing amounts of the HIV-1 PR inhibitor, SQV, measured at 30°C for 3 h. After
labeling reaction in the presence of 2 µM substrates and 200 nM FlAsH reagent, the
indicated concentration of SQV and 50 nM protease were added, and FP values were
measured. The FP values obtained from the reaction in the absence of both SQV and PR was
added for comparison. (C) Coomassie Blue staining of the protein samples after FP
measurements. The level of cleavage at each SQV concentration is shown. The uncleaved
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substrate, MA/CAΔ, is depicted as GST-MA-CAN and two cleavage products are depicted
as GST-MA and CAN.
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HTS assay validation in 384-well plates. (A) Design of each 384-well plate tested for HTS
validation of the assay. Individual 384-well plate includes two columns of positive controls
shown in red and two columns of negative controls shown in green. The positive control
wells contain MA/CAΔ substrate plus wild-type PR and the negative control wells contain
MA/CAΔ substrate plus heat-inactivated PR. The reactions in the wells shown in yellow are
the same as the one in the positive controls. The validations were performed on three
different days, testing two 384-well plates on each day. (B) Well-to-well variation for the
positive and negative controls shown in the scatter plot of the data from the plate 1. Data
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from the negative controls are denoted as −PR and data from the rest of the wells including
the positive controls are denoted as +PR.
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Pilot screening using the LOPAC1208 compound library. (A) The percent inhibition of the
cleavage reaction of the MA/CAΔ substrate by the HIV-1 PR in the presence of each
compound. Design of 384-well plates used for screening LOPAC1208 compound library is
the same as that used for HTS assay validation except that the wells shown in yellow contain
a compound. Neither positive nor negative control wells contain a compound. Each
compound was screened in duplicate and each dot represents the result from the individual
compound. All the data from the duplicate screening denoted as testA and testB were
plotted. Two compounds displaying approximately 50% of inhibitory activity are circled.
(B) Bland-Altman plot of the difference between % inhibition of testA and % inhibition of
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testB plotted against the mean of % inhibition of testA and % inhibition of testB. The mean
difference ± 2 standard deviations (95% limits of agreement) are shown with dashed lines.
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Gel-based secondary assay using an alternative Gag substrate, p15-C2S, containing a
cleavage site between SP2 and p6. (A) Fluorescence image of gel-based assay employing
two substrates, MA/CA and p15-C2S labeled with the FlAsH reagent in the same reaction.
Proteolysis was performed by the addition of 0.34 µM HIV-1 PR at 30°C. Proteolysis was
stopped at the various time points shown above the gel image by taking aliquots for further
SDS-PAGE analysis. The aliquot for 0 min time point was taken before the enzyme was
added. Fluorescently labeled proteins were visualized by fluorescence imaging. Filled
arrowheads indicate MA/CA substrate and its cleavage product (CA) and open arrowheads
indicate p15-C2S substrate and its cleavage product (p6). The domains shown in black
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indicate the location where the FlAsH reagent binding occurred. The cleavage sites are
shown with scissors. (B) Band intensity of the uncleaved and cleaved proteins was
quantified and cleavage rates were calculated using the time points in which the percentage
amounts of the cleavage products are within 50%. The slope value obtained from linear
regression analysis was used to compare the cleavage rate between two substrates.
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